The growth of the BCL-2 inhibitors market is expected to be driven primarily by rising incidence, increased awareness and access to treatment, and the launch of emerging drugs such as Lisaftoclax ...

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...

Lung cancer is the leading cause of death from malignancy in people and over 85% of these patients eventually die from disseminated disease. Paclitaxel (TAX) is widely used as an antimicrotubule agent ...

The growth of the BCL-2 inhibitors market is expected to be driven primarily by rising incidence, increased awareness and access to treatment, and the launch of emerging drugs such as Lisaftoclax ...